Mantle Cell Lymphoma
The latest news, research, and perspectives in mantle cell lymphoma (MCL). In MCL, a malignant B lymphocyte in the outer edge, or mantle zone, of a lymph node follicle grows uncontrollably, resulting in the accumulation of lymphoma cells.
Advertisement
The anti-CD19 autologous CAR-T-cell therapy was approved for use in adults with relapsed or refractory disease.
In a retrospective study bendamustine compared favorably with the cyclophosphamide plus fludarabine lymphodepletion regimen.
The results from a phase I seamless design study are relevant especially to older patients and those with high-risk disease.
The study compared treatment response based on prior systemic lines of therapy and prior BTK inhibition in patients with MCL.
The 15-month PFS was approximately 33% for patients who were BTK exposed and over 50% for patients who were BTK naïve.
After five and a half years of follow-up, rituximab maintenance significantly improved survival outcomes.
Advertisement
Granted under FDA Priority Review, the approval is based on results from the MCL cohort of the TRANSCEND NHL 001 study.
Dr. Maddocks hopes that current trials will help us “spring forward” into a chemotherapy-free approach to treating MCL.
Liso-cel received regulatory acceptances from the US FDA and the Ministry of Health, Labour and Welfare in Japan for FL.
Dr. Eyre and the hosts discuss lymphoma abstracts from ASH 2023, including the FLAIR trial and the SYMPATICO trial.
Narazaciclib plus ibrutinib regulated signatures associated with DNA repair, P53 signaling, and glycolytic activity.
Progression-free survival was significantly prolonged with the combination compared with a placebo.
The trial established the recommended phase II dose of acalabrutinib, venetoclax, and obinutuzumab.
Compared to past studies, acalabrutinib plus rituximab improves post-chemotherapy induction CR rates and MRD negativity.
The median overall survival was 44.9 months with ibrutinib plus venetoclax versus 38.6 months with ibrutinib plus placebo.
The data came from ZUMA-2, a phase II, open-label, multicenter, single-arm trial in which participants received brexu-cel.
The study evaluated ROR1 expression levels in a panel of MCL cell lines and primary patient samples.
Pirtobrutinib is a non-covalent (reversible) BTK inhibitor that inhibits both wild-type and C481-mutant BTK.
Study authors noted that the findings underscore the need for tailored approaches to MRD testing.
Jonathon B. Cohen, MD, MS, reported these updated results from the BRUIN trial.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.